EODData

MEMBERSHIP REGISTER LOG IN

FRA, DUL: Alnylam Pharmaceuticals Inc

04 Sep 2025
LAST:

380.8

CHANGE:
 0.60		OPEN:
380.8		HIGH:
380.8		ASK:
0.0		VOLUME:
3
CHG(%):
0.16		PREV:
380.2		LOW:
380.8		BID:
0.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
04 Sep 25380.8380.8380.8380.83
03 Sep 25380.2380.2380.2380.23
02 Sep 25378.3383.0378.3383.03
01 Sep 25377.4377.4377.4377.41
29 Aug 25384.2384.2384.2384.21
28 Aug 25388.0388.0388.0388.01
27 Aug 25385.6385.6385.6385.61
26 Aug 25378.6378.6378.6378.61
25 Aug 25384.9384.9384.9384.91
22 Aug 25400.7400.7400.7400.71

COMPANY PROFILE

Name:Alnylam Pharmaceuticals Inc
About:Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Sector:Healthcare
Industry:Biotechnology
Address:675 West Kendall Street, Cambridge, MA, United States, 02142
Website:https://www.alnylam.com
ISIN:US02043Q1076
LEI:529900S3ZI14OWRJII50

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:381.12
MA10:384.34
MA20:382.08
MA50:326.30
MA100:286.19
MA200:261.98
STO9:32.08
STO14:14.59
RSI14:50.83
WPR14:-85.41
MTM14:-7.10
ROC14:-0.02
ATR:5.16
Week High:388.00
Week Low:377.40
Month High:400.70
Month Low:341.82
Year High:400.70
Year Low:197.44